A Study of Nipocalimab in Reducing the Risk of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT)

Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2024
The purpose of this study is to evaluate the effectiveness of nipocalimab compared with placebo in reducing the risk of fetal and neonatal alloimmune thrombocytopenia (FNAIT).
Epistemonikos ID: 02099c4c85e3428ec9d85a0432e034903be1c470
First added on: Jul 01, 2024